Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
Panelists discuss how medical professionals select PSMA PET tracers based on factors such as diagnostic accuracy, tracer availability, patient-specific considerations, and logistical aspects such as half-life and production facilities. Fluorine-18 (^18F)–labeled tracers, such as ^18F-PSMA-1007, offer logistical advantages due to their longer half-life and higher image resolution, facilitating broader clinical application.
EP: 1.The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
EP: 2.PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
EP: 3.Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
EP: 4.Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
EP: 5.PSMA PET Imaging in Prostate Cancer Staging: Guiding Initial Diagnosis and Treatment Decisions
EP: 6.PSMA PET Imaging in Biochemical Recurrence: Clinical Approaches and Data-Driven Decisions
EP: 7.Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
EP: 8.Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
EP: 9.Utilizing PSMA PET Imaging in Metastatic Prostate Cancer to Guide Treatment Strategies
EP: 10.Case Discussion: Integrating PSMA PET for Focal Boost Optimization
EP: 11.Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
EP: 12.Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Video content above is prompted by the following:
- What factors do you consider when selecting a PSMA PET tracer for a particular patient or clinical scenario?
- When might you opt for F18 vs Ga58, and how do available data inform your decision?
- Meta-analysis F18 vs G68 (Huang et al. Prostate Cancer. 2023)
- Do you still see a role for Axumin? If so, in what scenarios?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
